[admin]

Introduction: The Stability Question Behind Every Tumor Marker Result

Serum tumor marker testing sits at the center of cancer management — tracking disease progression, assessing treatment response, and detecting recurrence after treatment. Tumor markers are often proteins, which makes the reagent that carries them through a test run as consequential as the assay itself. When a laboratory runs tPSA, fPSA, CEA, or any other marker across a working day, the question is not only whether the test can detect the analyte, but whether it performs the same way in the first run and the last, in one facility and another, after storage and transport.

Lyophilization — freeze-drying reagents into a dry micro format — is a direct answer to that question. Poclight has built both its serum tumor marker menu and its C5000 Dry Micro System around this reagent principle, positioning reagent stability as an operational asset rather than a technical footnote.

Why Lyophilized Reagents Change the Operational Picture

Room-Temperature Storage and Transport

The complementary reagent supplied with the C5000 Dry Micro System is lyophilized, with room temperature storage and transport; a liquid form is also available. This matters for laboratories that cannot guarantee uninterrupted cold-chain handling, and for settings where shipments, storage space, or power conditions are less predictable. Removing the dependence on continuous refrigeration simplifies inventory planning and reduces the handling steps that sit between receiving a reagent and using it.

Wash-Free Separation Without Magnetic Beads

The system uses a dry micro reagent format with wash-free separation, no magnetic beads, and no complex liquid path. Each of these design choices removes a source of variability. Wash steps introduce fluid handling, timing, and residual-volume variables; magnetic bead separation introduces particle behavior and one more consumable to control. Minimizing both reduces the number of places where a stable reagent can nonetheless produce an unstable result.

Semi-Automatic, Portable Operation

The C5000 is a semi-automatic, portable dry micro detection system for rapid serum tumor marker testing. Portability plus room-temperature reagent storage means the same reagent format can serve a central laboratory and a decentralized clinical department without a different handling protocol for each.

Technical Profile of the C5000 Dry Micro System

The platform’s stated technical metrics are:

• Technology platform: C5000 Dry Micro System with a dry micro reagent format, lyophilized and liquid complementary reagents, wash-free separation, no magnetic beads, and no complex liquid path
• First sample result: 3 minutes
• Channel capacity: 7-channel
• Accuracy: CV < 5%
• Throughput: 80 tests/hour
• Weight: ≤ 8.5 kg

In the system’s product specification, accuracy is stated as CV < 3%. Either way, the platform is built to hold analytical precision while shortening the time between sample and answer — a first result in 3 minutes at a throughput of 80 tests per hour.

Platform Capabilities and Compatibility

Operation is through a touch screen interface, and the system supports LIS/HIS transmission with real-time information sharing. For a hospital clinical department or laboratory information environment, that connectivity decides whether a fast result actually reaches the clinician fast. A three-minute result that must be transcribed by hand does not deliver the operational benefit it promises; a result that lands in the laboratory information system in real time does.

Tumor Marker Tests Built on the Same Reagent Discipline

Poclight’s serum tumor marker menu covers seven individual assays: tPSA, fPSA, CEA, AFP, CYFRA21-1, CA19-9, and CA125.

tPSA is a prostate cancer screening marker used to identify patients who need further investigation after an elevated result. Levels above 4 ng/mL trigger additional investigation, but low specificity in benign prostatic hyperplasia and prostatitis can create unnecessary biopsy burden. tPSA provides an organ-specific signal, with levels correlating with tumor burden and metastasis risk.

fPSA is the companion marker that refines detection in the gray zone. When tPSA falls in the 4–10 ng/mL range and the fPSA/tPSA ratio is below 0.16, prostate cancer detection specificity increases by 17.4% and unnecessary biopsies are reduced. The ratio reflects altered PSA isoforms — higher fPSA in benign conditions, lower fPSA in malignancies.

CEA is a pan-cancer monitoring marker for recurrence and treatment response in colorectal, gastric, pancreatic, lung, and breast cancers. Serial postoperative measurements predict recurrence, and rising CEA can precede imaging findings, enabling earlier clinical investigation. U.S. clinical practice guidelines recommend obtaining a CEA level before elective colon cancer surgery for post-surgical risk management. Its limitation is noted plainly: low specificity in smokers and inflammation means it is not diagnostic by itself.

Combined Detection Panels: Where Panel Data Depends on Reagent Consistency

Because individual markers have documented gaps, Poclight offers nine clinical combined detection panels, each calibrated to a specific tumor type.

The Prostate Cancer panel (tPSA + fPSA, F/T ratio) reduces false positives by 30% in the gray zone, with panel sensitivity of 44–67% and specificity of 81–87%. The Hepatocellular Carcinoma panel (AFP + AFP-L3 + DCP) reaches 70–85% sensitivity and 80–90% specificity, improving on AFP alone, which produces 30–40% false negatives in early HCC. The NSCLC Squamous panel (CYFRA21-1 + SCC) delivers 88% sensitivity and 74% specificity, helping distinguish squamous from adenocarcinoma. The NSCLC Adenocarcinoma panel (CEA + CYFRA21-1 + CA125) is designed for early-stage detection at 75% sensitivity and 70% specificity.

For gastrointestinal and related cancers, the Gastric Cancer panel (CEA + CA19-9 + CA72-4) achieves 70–86% sensitivity and 80–88% specificity, with CA72-4 specific for gastric origin. The Pancreatic Cancer panel (CEA + CA19-9 + CA125) reaches 82% sensitivity and 75% specificity and can help predict resectability — relevant given that CA19-9 alone produces false negatives in Lewis antigen-negative individuals, 5–10% of the population. The Colorectal Cancer panel (CEA + CA19-9 + CA242) supports post-surgical monitoring and liver metastasis detection at 70–92% sensitivity and 85–90% specificity. The Ovarian Cancer panel (CA125 + HE4) achieves 76–94% sensitivity and 75–95% specificity, with 93.8% accuracy; combining CA125 with HE4 improves specificity to 95% through the ROMA index.

Panels are only as reproducible as the reagents running them. A three-marker panel multiplies the number of reagent lots, storage conditions, and handling steps that must behave identically from run to run — which is precisely why a lyophilized, wash-free reagent format is an operational decision and not merely a formulation preference.

Market Recognition and Clinical Consensus

Several external reference points support the marker menu Poclight serves. PSA Consensus 2024 (UK) states that the PSA blood test is the first step in the prostate cancer diagnostic pathway and is a low-cost, safe, and effective way of identifying men who would benefit from further testing. U.S. clinical practice guidelines recommend obtaining CEA before elective colon cancer surgery. Chinese expert consensus work has highlighted biannual ultrasound and AFP as a cost-effective HCC screening strategy, and separately concluded that CYFRA21-1 alone shows less positive correlation in NSCLC prognosis, while combining CEA and SCC tests helps distinguish early-stage NSCLC from benign lung disease presenting with suspicious pulmonary masses.

Conclusion: Stability as the Foundation of Throughput

Speed, throughput, and connectivity are the visible benefits of the C5000 Dry Micro System — a first sample result in 3 minutes, 80 tests per hour, 7 channels, ≤ 8.5 kg, and real-time LIS/HIS sharing across urology, gastrointestinal surgery, gynecology, oncology, respiratory, hepatobiliary surgery, and gastroenterology settings. None of that holds up without reagent stability underneath it.

Lyophilized reagents with room temperature storage and transport, a wash-free separation design without magnetic beads, and no complex liquid path do not simply reduce maintenance — they remove the operational variables that turn a technically sound assay into an inconsistent one. For laboratories managing a 16-item product and service portfolio spanning tPSA, fPSA, CEA, AFP, CYFRA21-1, CA19-9, CA125, nine combined detection panels, and the C5000 Dry Micro System itself, that stability is what makes consistent daily performance achievable rather than aspirational.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts